We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2025

Session

Lower GI
Digital Poster
Clinical
Surgery after neo-adjuvant long course radiotherapy in locally advanced rectal cancer : timing matters . A retrospective matched paired control study.
GRAZIA Lazzari , Italy
E25-1299
Phase 1b/II trial of pembrolizumab plus standard radiotherapy with chemotherapy in Squamous Cell Carcinoma of anus (CORINTH): Cohorts safety data
Lisette Nixon, United Kingdom
E25-1478
FAPI PET/CT in anal and rectal cancer – first clinical experience with an early imaging PET protocol for radiotherapy planning
Simone Ferdinandus, Germany
E25-1611
Novel approach to rectal cancer in inflammatory bowel disease: preliminary results from a hyperfractionated-accelerated chemoradiation protocol.
Silvia Cammelli, Italy
E25-1760
Long-term clinical outcomes following intensified total neoadjuvant therapy for locally advanced rectal cancer: a single-centre experience
Carolina Gentili, Italy
E25-1954
Short course radiotherapy for locally advanced rectal cancer contoured like long course: toxicity profile
Margherita Rotondi, Italy
E25-1980
Preoperative Immunomodulatory radiotherapy: feasibility, safety, and surgeon reported outcomes
JULIEN PIERRARD, Belgium
E25-1983
The management of anal squamous cell carcinoma in frail and elderly patients – is 30Gy enough?
Christakis Agathokleous, United Kingdom
E25-2008
Feasibility and Tolerance of Deep Hyperthermia Combined with Radiochemotherapy in Locally Advanced Rectal Cancer: First Spanish Experience
Barbara Gabriela Salas Salas, Spain
E25-222
Quality of Life Assessment in Czech Patients with Anal Cancer: A Multicentre Study Using the EORTC QLQ-C30, QLQ-ANL27 and LARS questionnaires
Radka Lohynska, Czech Republic
E25-2165
Dosimetric and clinical impact of bone marrow-sparing radiotherapy for anal cancer: A systematic review
Jasmine Wen-Yao Chen, Canada
E25-2215
First implementation of an All-in-One solution with full automatic workflow during for rectal cancer based on an integrated CT-linac
Luqi Wang, China
E25-2290
Elective nodal CTV in early anal cancer: A systematic review and meta-analysis on the risk of recurrence in the upper pelvic and external iliac LNS
Joanna Socha, Poland
E25-2297
Total neo-adjuvant treatment of locally advanced rectal cancer using short-course MRI-guided radiotherapy with simultaneous integrated boost.
Koen Kortbeek, Belgium
E25-2371
Long-Term Analysis of Chemoradiotherapy in anal cancer: from predictive factors to survival outcomes and toxicities – a single-institution analysis
Catarina van der Elzen, Portugal
E25-2486
Early indication of treatment response in rectal cancer using sequential diffusion-weighted imaging at a 1.5 T MR-linac
Johanna Austrheim Hundvin, Norway
E25-2547
CBCT-based online Adaptive Radiotherapy in rectal cancer: workflow and decision pathways.
Maribel Martínez, Spain
E25-2950
Inflammatory Biomarkers and LIPI Score to Predict Treatment Response in Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy
Zilan Başkan, Turkey
E25-2959
Evolution of rectal volume on weekly CBCT during neoadjuvant chemoradiotherapy and tumor response in locally advanced rectal cancer.
Sasha Benichou, France
E25-243
Prognostic factors for disease-free interval in patients with rectal cancer treated with neoadjuvant chemoradiotherapy and dose intensification
Mladen Marinković, Serbia
E25-3028
Inter-fraction variability of the mesorectum during long-course radiotherapy in rectal cancer
Marcelo Parra, Mexico
E25-3075
Lower FDG PET/C? SUVmax is associated with better response to neoadjuvant radiotherapy combined with chemotherapy in patients with rectal carcinoma
Temenuzhka Radeva-Petkova , Bulgaria
E25-3080
SBRT in Metastatic Colorectal Cancer: Managing Oligoprogressive or Oligopersistent Lesions and Shifting Systemic Therapy – Single-Center Analysis
Eliana La Rocca, Italy
E25-3106
How predict complete response after definitive chemoradiotherapy for locally advanced SCC of the anal canal: the role of sequential PET/CT imaging
marianna valzano, Italy
E25-3118
Pulmonary Oligometastases from Colorectal Carcinoma Treated with Stereotactic Body Radiotherapy: Experience of a Single Institution
Alice Alves, Portugal
E25-3130
Sequencing of chemotherapy in total neoadjuvant treatment for rectal cancer does not predict radiation-induced lymphopenia
Miha Orazem, Slovenia
E25-3305
hypofractionated proton therapy for primary intrahepatic cancers: time for a pivotal role? a systematic review and meta-analysis
Maria Giulia Vincini, Italy
E25-3381
Repeat SABR likely required for survival benefit in oligometastatic colorectal cancer: results from the prospective randomised SABR-SCAN trial
Joachim Widder, Austria
E25-259
Anal cancer treatment in a regional cancer centre with chemoradiotherapy: Outcomes, toxicity and rates of venous thromboembolism
James Francis Leach, United Kingdom
E25-3395
External Validation of Contouring Guidelines for Inguinal Lymph Node Irradiation in Anal Canal Cancer
Maria Antonietta Gambacorta, Italy
E25-3423
Total neoadjuvant treatment(TNT) followed by surgery in locally advanced rectal cancer: Three year’s experience of Bangladeshi tertiary level hospital
Nowshin Taslima Hossain, Bangladesh
E25-3465
short-course strategy for rectal cancer: for whom and why? a real-world exploratory analysis
Maria Giulia Vincini, Italy
E25-3476
Risk-Stratified Follow-up in Rectal Cancer Patients with Clinical Complete Response: A Tailored Approach from Watch-and-Wait Strategy
Chen Yang, China
E25-3481
Prospective trial of organ preservation in patients with rectal cancer: preliminary outcomes in our center.
Victoria Vera Barragán, Spain
E25-3523
Unlocking Recovery: The Role of Dosimetry and Clinical Insights in Pelvic Floor Rehabilitation for Rectal Cancer
Gloria Guardia, Spain
E25-3701
Role of surgery in the survival of rectal cancer after neoadjuvant chemoradiotherapy in patients without complete clinical response
Reza Ghalehtaki, Iran Islamic Republic of
E25-3736
Cure vs. toxicity: quantifying preferences for non-surgical management of rectal cancer using a prospective discrete choice experiment study
Edward Webb, United Kingdom
E25-3809
Impact of glutamine-peptide-formula on acute-toxicity-symptoms in rectal-cancer neoadjuvant Chemo-radiotherapy treatment
Barbara Gabriela Salas Salas, Spain
E25-294
Anal Cancer Survivorship: A Comprehensive Evaluation Using Patient-Reported Outcomes (PROs) (ClinicalTrials.gov NCT06364579)
Maria Antonietta Gambacorta, Italy
E25-3871
overdosed boost (SIB) of radiotherapy on locally advanced rectal cancer
donatella caivano, Italy
E25-3960
Induction or consolidation strategy in total neoadyuvant therapy?
Gloria Guardia, Spain
E25-4050
Comparative analysis of acute toxicity in Total Neoadjuvant Therapy for locally advanced rectal cancer using Long-Course vs Short-Course Radiotherapy
Nerea Ugarte Ruiz de Aguirre, Spain
E25-4076
WATCH AND WAIT PROTOCOL IN RECTAL CANCER: FIRST RESULTS IN A SINGLE CENTRE
Marta Pérez Cobos, Spain
E25-4111
IMPACT OF LATERAL LYMPH NODES ON CLINICAL OUTCOMES IN NEOADJUVANT RADIOCHEMOTHERAPY FOR LOCALLY ADVANCED RECTAL CANCER: A MONOINSTITUTIONAL EXPERIENCE
Marco Lucarelli, Italy
E25-4149
Survival Analysis and Prognostic Factors in Rectal Cancer treated with Hypofractionated Radiotherapy: Real-World impact of Total Neoadjuvant Therapy.
Ricardo Oyarzun Silva, Spain
E25-4215
PATHOLOGICAL COMPLETE RESPONSE AND MRI FEATURES IN LOCALLY ADVANCED RECTAL CANCER: A MONO INSTITUTIONAL EXPERIENCE
Marco Lucarelli, Italy
E25-4229
A novel CT radiomics-based machine learning approach: predicting NAR and overall survival in rectal cancer patients treated with TNT
Gabriel Lazcano Álvarez, Chile
E25-4240
Where do we stand with the rectal boost RT? A systematic review and meta-analysis
JULIEN PIERRARD, Belgium
E25-323
Real-world clinical results of total neoadjuvant therapy in locally advanced rectal cancer: a single-institution study over four years
Zsófia Együd, Hungary
E25-4392
Bowel Function and Bother After Radiation Therapy in Prostate Cancer Patients: Insights from a Prospective Study
FATIMA ZAHRA CHRAA, Morocco
E25-4499
Radiotherapy for T1 anal cancer: Single-institution analysis including brachytherapy over 30 years
Johannes Knoth, Austria
E25-575
Optimizing Outcomes in Locally Advanced Rectal Cancer: Watch-and-Wait Strategy with Hypofractionated Radiotherapy and Integrated Boost
Maria del Carmen Saiz Guisasola , Spain
E25-764
Adjuvant chemotherapy after neoadjuvant chemoradiotherapy and surgery for rectal cancer: assessing its continued relevance and effectiveness.
Febin Antony , India
E25-1297